Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07058090
PHASE1

Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi

Sponsor: Liaquat National Hospital & Medical College

View on ClinicalTrials.gov

Summary

OBJECTIVE : To compare the outcome of treatment with silymarin or N-acetyl cysteine in patients taking anti-tuberculous drugs for tuberculosis at Tertiary Care Hospital, Karachi. SAMPLE SELECTION : Patients presenting with tuberculosis previously not on anti-tuberculous drugs, between 40-80 years of age, both genders will be included .Patients with history of alcohol use,Discontinuation of drug due to other adverse effects except hepatotoxicity ,Inadequate date of laboratory testing at baseline or 2 to 4 weeks after treatment initiation, Cases with human immunodeficiency virus (HIV) co-infection, viral hepatitis, or suspected mal absorption (e.g., gastrointestinal disease or diarrhea) ,Chronic liver disease, COPD, asthma, myocardial infarction, chronic kidney disease and stroke will be excluded

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

410

Start Date

2025-07

Completion Date

2026-05

Last Updated

2025-07-10

Healthy Volunteers

No

Interventions

DRUG

Silymarin 420 mg

silymarin group received silymarin 140mg thrice daily along with antituberculous drugs for 14 days

DRUG

N Acetyl Cysteine

N- acetylcysteine group will receive N-acetylcysteine 900mg once daily with antituberculous drugs for 14 days

DRUG

Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)

Antituberculous drugs only